Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

107.80
Delayed Data
As of Jun 15
 +0.74 / +0.69%
Today’s Change
70.76
Today|||52-Week Range
153.99
-15.15%
Year-to-Date

Today’s Trading

Previous close107.06
Today’s open106.70
Day’s range105.85 - 108.00
Volume1,116,608
Average volume (3 months)953,952
Market cap$10.4B
Data as of 4:00pm ET, 06/15/2018

Growth & Valuation

Earnings growth (last year)-13.15%
Earnings growth (this year)-30.41%
Earnings growth (next 5 years)+163.00%
Revenue growth (last year)+90.66%
P/E ratioNM
Price/Sales127.96
Price/Book5.82

Competitors

 Today’s
change
Today’s
% change
ALKSAlkermes Plc+0.16+0.32%
SGENSeattle Genetics Inc-0.38-0.58%
TSROTESARO Inc-1.66-4.01%
JAZZJazz Pharmaceuticals...+0.87+0.49%
Data as of 4:15pm ET, 06/15/2018

Financials

Next reporting dateAugust 9, 2018
EPS forecast (this quarter)-$1.78
Annual revenue (last year)$89.9M
Annual profit (last year)-$490.9M
Net profit margin-545.95%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts